Geode Capital Management LLC Boosts Holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI)

Geode Capital Management LLC raised its position in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 4.6% in the 3rd quarter, Holdings Channel.com reports. The fund owned 133,550 shares of the company’s stock after acquiring an additional 5,861 shares during the quarter. Geode Capital Management LLC’s holdings in Greenwich LifeSciences were worth $1,919,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rhumbline Advisers acquired a new stake in shares of Greenwich LifeSciences in the 2nd quarter worth $117,000. Barclays PLC increased its position in Greenwich LifeSciences by 323.3% during the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after buying an additional 6,538 shares in the last quarter. Garden State Investment Advisory Services LLC purchased a new stake in Greenwich LifeSciences in the third quarter valued at about $253,000. Bank of New York Mellon Corp acquired a new stake in Greenwich LifeSciences in the second quarter worth about $264,000. Finally, State Street Corp boosted its holdings in Greenwich LifeSciences by 4.4% in the third quarter. State Street Corp now owns 71,408 shares of the company’s stock worth $1,026,000 after acquiring an additional 3,005 shares in the last quarter. 4.16% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Greenwich LifeSciences news, CEO Snehal Patel purchased 3,200 shares of Greenwich LifeSciences stock in a transaction on Monday, December 30th. The stock was bought at an average cost of $11.12 per share, with a total value of $35,584.00. Following the transaction, the chief executive officer now owns 5,539,302 shares of the company’s stock, valued at $61,597,038.24. This represents a 0.06 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have purchased 8,000 shares of company stock valued at $97,184. Insiders own 51.67% of the company’s stock.

Greenwich LifeSciences Stock Down 3.3 %

GLSI opened at $13.35 on Thursday. The company has a market cap of $175.49 million, a P/E ratio of -16.69 and a beta of 1.66. The firm’s 50-day moving average price is $13.15 and its 200-day moving average price is $14.13. Greenwich LifeSciences, Inc. has a 52-week low of $8.00 and a 52-week high of $21.44.

Greenwich LifeSciences Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.